Chimerin 2
β-chimaerin（ベータ-キメリン、ベータ-カイメリン）はヒトにおいてCHN2遺伝子にコードされているタンパク質である[4][5]。
この遺伝子はchimerinファミリーのメンバーであり、ホルボールエステル/DAGタイプ亜鉛フィンガー、Rho-GAPドメイン、SH2ドメインを持つタンパク質をコードしている。このタンパク質は、リン脂質結合およびジアシルグリセロール (DAG) の結合が誘導するタンパク質の細胞質ゾルからゴルジ体膜への移行によって制御されているGTPアーゼ活性化タンパク質活性を有する。このタンパク質は平滑筋細胞の増殖および移動に役割を果たしている。この遺伝子の発現の減少は悪性度の高い神経膠腫および乳がんと関連しており、この遺伝子の発現の上昇はリンパ腫と関連している。この遺伝子の変異は、ヒトの統合失調症と関連している。異なるアイソフォームをコードしている選択的転写スプライシングバリアントが同定されている[5]。
脚注
[編集]- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000004633 - Ensembl, May 2017
- ^ Human PubMed Reference:
- ^ Mouse PubMed Reference:
- ^ Leung T, How BE, Manser E, Lim L (Jun 1994), “Cerebellar beta 2-chimaerin, a GTPase-activating protein for p21 ras-related rac is specifically expressed in granule cells and has a unique N-terminal SH2 domain”, J Biol Chem 269 (17): 12888–92, PMID 8175705
- ^ a b “Entrez Gene: CHN2 chimerin (chimaerin) 2”. 2012年1月26日閲覧。
推薦文献
[編集]- Yuan S, Miller DW, Barnett GH, et al. (1995), “Identification and characterization of human beta 2-chimaerin: association with malignant transformation in astrocytoma”, Cancer Res. 55 (15): 3456–61, PMID 7614486
- Caloca MJ, Fernandez N, Lewin NE, et al. (1997), “Beta2-chimaerin is a high affinity receptor for the phorbol ester tumor promoters”, J. Biol. Chem. 272 (42): 26488–96, doi:10.1074/jbc.272.42.26488, PMID 9334226
- Caloca MJ, Garcia-Bermejo ML, Blumberg PM, et al. (1999), “beta2-chimaerin is a novel target for diacylglycerol: binding properties and changes in subcellular localization mediated by ligand binding to its C1 domain”, Proc. Natl. Acad. Sci. U.S.A. 96 (21): 11854–9, doi:10.1073/pnas.96.21.11854, PMC 18376, PMID 10518540
- Caloca MJ, Wang H, Delemos A, et al. (2001), “Phorbol esters and related analogs regulate the subcellular localization of beta 2-chimaerin, a non-protein kinase C phorbol ester receptor”, J. Biol. Chem. 276 (21): 18303–12, doi:10.1074/jbc.M011368200, PMID 11278894
- Wang H, Kazanietz MG (2002), “Chimaerins, novel non-protein kinase C phorbol ester receptors, associate with Tmp21-I (p23): evidence for a novel anchoring mechanism involving the chimaerin C1 domain”, J. Biol. Chem. 277 (6): 4541–50, doi:10.1074/jbc.M107150200, PMID 11689559
- Strausberg RL, Feingold EA, Grouse LH, et al. (2003), “Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences”, Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903, doi:10.1073/pnas.242603899, PMC 139241, PMID 12477932
- Scherer SW, Cheung J, MacDonald JR, et al. (2003), “Human chromosome 7: DNA sequence and biology”, Science 300 (5620): 767–72, doi:10.1126/science.1083423, PMC 2882961, PMID 12690205
- Nishiu M, Yanagawa R, Nakatsuka S, et al. (2003), “Microarray analysis of gene-expression profiles in diffuse large B-cell lymphoma: identification of genes related to disease progression”, Jpn. J. Cancer Res. 93 (8): 894–901, PMID 12716467
- Hillier LW, Fulton RS, Fulton LA, et al. (2003), “The DNA sequence of human chromosome 7”, Nature 424 (6945): 157–64, doi:10.1038/nature01782, PMID 12853948
- Caloca MJ, Wang H, Kazanietz MG (2004), “Characterization of the Rac-GAP (Rac-GTPase-activating protein) activity of beta2-chimaerin, a 'non-protein kinase C' phorbol ester receptor”, Biochem. J. 375 (Pt 2): 313–21, doi:10.1042/BJ20030727, PMC 1223697, PMID 12877655
- Ota T, Suzuki Y, Nishikawa T, et al. (2004), “Complete sequencing and characterization of 21,243 full-length human cDNAs”, Nat. Genet. 36 (1): 40–5, doi:10.1038/ng1285, PMID 14702039
- Gerhard DS, Wagner L, Feingold EA, et al. (2004), “The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)”, Genome Res. 14 (10B): 2121–7, doi:10.1101/gr.2596504, PMC 528928, PMID 15489334
- Canagarajah B, Leskow FC, Ho JY, et al. (2004), “Structural mechanism for lipid activation of the Rac-specific GAP, beta2-chimaerin”, Cell 119 (3): 407–18, doi:10.1016/j.cell.2004.10.012, PMID 15507211
- Hashimoto R, Yoshida M, Kunugi H, et al. (2005), “A missense polymorphism (H204R) of a Rho GTPase-activating protein, the chimerin 2 gene, is associated with schizophrenia in men”, Schizophrenia Research 73 (2–3): 383–5, doi:10.1016/j.schres.2004.01.017, PMID 15653288
- Barrios-Rodiles M, Brown KR, Ozdamar B, et al. (2005), “High-throughput mapping of a dynamic signaling network in mammalian cells”, Science 307 (5715): 1621–5, doi:10.1126/science.1105776, PMID 15761153
- Yang C, Liu Y, Leskow FC, et al. (2005), “Rac-GAP-dependent inhibition of breast cancer cell proliferation by {beta}2-chimerin.”, J. Biol. Chem. 280 (26): 24363–70, doi:10.1074/jbc.M411629200, PMID 15863513
- Kimura K, Wakamatsu A, Suzuki Y, et al. (2006), “Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes”, Genome Res. 16 (1): 55–65, doi:10.1101/gr.4039406, PMC 1356129, PMID 16344560
- Siliceo M, García-Bernal D, Carrasco S, et al. (2006), “Beta2-chimaerin provides a diacylglycerol-dependent mechanism for regulation of adhesion and chemotaxis of T cells”, J. Cell. Sci. 119 (Pt 1): 141–52, doi:10.1242/jcs.02722, PMID 16352660
- Yang C, Liu Y, Lemmon MA, Kazanietz MG (2006), “Essential role for Rac in heregulin beta1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4”, Mol. Cell. Biol. 26 (3): 831–42, doi:10.1128/MCB.26.3.831-842.2006, PMC 1347034, PMID 16428439